At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Lanthanum carbonate +1 moredrug
Likely dose
Lanthanum carbonate 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating Lanthanum carbonate and Placebo for Chronic Kidney Disease. Completed, enrolled 35 participants across 1 site.
Detailed Summary
To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartDec 2010
Primary CompletionApr 2012
TodayJul 2026
First PostedMay 21, 2010
Enrollment StartDec 6, 2010
Primary CompletionApr 16, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.1 years ago
Interventions
Lanthanum carbonatedrug
1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
Placebodrug
Matching placebo chewable tablets administered 3 times a day for 12 weeks